PxWire Archive
2011
January-March 2012, Volume 5, Issue 1
(PDF, HTML)
To start off this issue, we identify ten key outcomes to pursue in order to make progress in beginning to end the AIDS epidemic. This issue also covers Gilead Science’s submission to the FDA for a label change for TDF/FTC (brand name Truvada); the closure of the 1% tenofovir gel arm of the VOICE trial; new trials launched this quarter; the first meeting of Project ARM (Africa for Rectal Microbicides).
October-December 2011, Volume 4, Issue 4
(PDF, HTML)
This issue includes updates on what will come next for the AIDS vaccine regimen that showed modest efficacy in the trial known as RV144; the recent VOICE trial modification; progress in demonstration projects, public health guidance and regulatory decision-making around PrEP in the United States; and, in addition to its usual features—a map of ongoing prevention trials and a timeline of efficacy trial results worldwide—you’ll find a new table of early-phase studies of ARV-based prevention strategies for HIV-negative people.
July-September 2011, Volume 4, Issue 3
(PDF, HTML)
This edition of Px Wire includes a feature on the new momentum to end the AIDS epidemic in light of the recent HPTN 052 results; an exploration of the progress in AIDS vaccine research and the need for evolving trial designs to accommodate new trial results such as those from HPTN 052 and iPrEx; and, as always, a centerspread with an updated timeline of biomedical HIV prevention efficacy trials and a world map showing where various strategies are being tested.
April-June 2011, Volume 4, Issue 2
(PDF, HTML)
Highlights in this issue include a feature on new momentum to end the AIDS epidemic in light of the new HPTN 052 results showing that early ARV treatment is highly protective against transmitting HIV to one’s sexual partner. You will also find an abbreviated roadmap highlighting sessions on the latest biomedical prevention updates at the upcoming 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. As appears each quarter, this issue includes a center foldout poster with an updated comprehensive timeline of efficacy trials of new biomedical HIV prevention worldwide and a world map showing where various strategies are being tested.
January-March 2011, Volume 4, Issue 1
(PDF, HTML)
This issue of Px Wire takes inventory of the regulatory, trial-planning and scientific agenda-setting steps that are being taken with respect to recent positive trial results. It reviews ongoing and proposed next steps that have been triggered by the Thai prime-boost AIDS vaccine trial, the CAPRISA 004 microbicide trial and the iPrEx trial of once-daily TDF/FTC for pre-exposure prophylaxis. Every issue of Px Wire includes a center poster with an updated comprehensive map and timeline of efficacy trials of biomedical HIV prevention worldwide and a calendar of upcoming events.
2010
October-December 2010, Volume 3, Number 4
Highlights in this issue include an update of the ongoing discussions around the follow-up of the CAPRISA 004 trial finding that 1% tenofovir gel reduces a women's risk of acquiring HIV by 39 percent overall and asks follow-up questions. What additional trials are being considered and why? Who will map the next steps? This issue also touches on the increasing discussions of "treatment as prevention" in reference to the possible use of antiretroviral treatment to reduce the risk of HIV transmission.
July-September 2010, Volume 3, Number 3
In this issue you'll find a brief review of highlights from the biannual International Microbicides Conference (M2010) held in May, including discussions of the potential opportunities and challenges of ARV-based prevention in topical and oral forms, new developments in delivery systems for microbicides and increasing recognition of rectal microbicides as a key area for exploration. This issue also covers what to expect with the forthcoming results of CAPRISA 004.
April-June 2010, Volume 3, Number 2
Highlights in this issue include: next steps in AIDS vaccine trials in the post-Thai vaccine trial (RV144) era; “test and treat” approach for prevention presented at CROI; a preview of AVAC Report 2010; information on the Microbicides 2010 Pre-Conference Advocacy Workshop; new funding for advocacy related to MSM and prevention research; six new clinical trials looking at enhanced prevention strategies.
January-March 2010, Volume 3, Number 1
Highlights in this issue of Px Wire include updates on: the results from MDP 301, a trial of the microbicide PRO 2000, which lay to rest its prospect as a viable microbicide; CDC’s newly modified PrEP trial (TDF2 in Botswana), which changed its status as an efficacy trial to a safety and behavioral study; the evolving effort to understand the Thai prime-boost AIDS vaccine results; recent NIH grants that nearly double global spending on rectal microbicides; and a timeline of 2010 trial milestones—what trial results are expected and what new studies are scheduled to commence?
2009
July-September 2009, Volume 2, Number 3
In addition to its usual features - a map of ongoing prevention trials and a timeline of efficacy trial results worldwide - this issue is designed to provide background and perspectives on some of the key issues and questions that have emerged as work around understanding and interpreting the results of the Thai trial moves forward.
April-June 2009, Volume 2, Number 2
This issue features multiple trial updates, including a review of the key findings from a trial of HSV-2 suppression. There's also a discussion of the results of the HPTN 035 microbicide trial (which tested PRO 2000 and BufferGel) and preparations for the upcoming results of MDP 301, also testing PRO 2000 gel. Additionally, this issue provides information on new trials including HVTN 505 (described in this year's first issue of Px Wire), which began screening participants in June, a new trial on intermittent PrEP scheduled to begin in July, and research to test a nipple shield to help prevent HIV transmission during breastfeeding.
January-March 2009, Volume 2, Number 1
Highlights in this issue of Px Wire include a report on data from the Step vaccine trial and animal studies of relevance to the proposed HVTN 505 trial of the NIH Vaccine Research Center DNA-Ad5 combination strategy presented at the Keystone Symposium on HIV prevention--an annual meeting focused on basic and preclinical science. This issue also reviews newly launched trials, lays out this year's upcoming trial milestones, and gives information on ordering the 2009 AVAC report on the prevention research field, to be released in May.
2008
October-December 2008, Volume 1, Number 4
In this year-end issue, you'll find AVAC's take on the year in prevention research, an update on the proposed AIDS vaccine trial HVTN 505, news on the female condom and microbicide trials and, as always, a freshly updated global map of ongoing efficacy and effectiveness trials, and a comprehensive timeline of biomedical HIV prevention efficacy trials.
July-September 2008, Volume 1, Number 3
Highlights in this issue of Px Wire include a discussion of the no-go decision on the proposed PAVE 100 vaccine trial (though the candidate may yet be tested), updates on women's input into male circumcision for HIV prevention, and AVAC's take on indelible moments and themes from the International AIDS Conference in Mexico City in August.
April-June 2008, Volume 1, Number. 2 / Abril--junio 2008, Vol. 1. No. 2 (en español)
Highlights in this issue of Px Wire include an update on the ongoing discussion regarding the proposed PAVE 100 vaccine trial, details on the first microbicide trial in pregnant women, a Mexico City preview, and notes on two recently released resources for the field, AVAC Report 2008: The Search Must Continue and the Global Campaign for Microbicides' Microbicides Essentials online learning tool.
January-March 2008, Volume 1, Number 1
This is the first issue of our new quarterly, Px Wire, which tracks key developments in the field of HIV prevention research, including the launch of new trials, results of ongoing studies, and an up-to-date tally of trials going on worldwide. Px Wire is designed to complement AVAC's other publications and to help advocates stay on top of the ever-changing field of HIV prevention research. It is the first one-stop source for information on the full range of HIV prevention research going on worldwide, including vaccines, microbicides, pre-exposure prophylaxis (PrEP), herpes simplex virus-2 treatment, male circumcision, cervical barrier methods, and partner treatment.
January-March 2012, Volume 5, Issue 1
(PDF, HTML)
To start off this issue, we identify ten key outcomes to pursue in order to make progress in beginning to end the AIDS epidemic. This issue also covers Gilead Science’s submission to the FDA for a label change for TDF/FTC (brand name Truvada); the closure of the 1% tenofovir gel arm of the VOICE trial; new trials launched this quarter; the first meeting of Project ARM (Africa for Rectal Microbicides).
October-December 2011, Volume 4, Issue 4
(PDF, HTML)
This issue includes updates on what will come next for the AIDS vaccine regimen that showed modest efficacy in the trial known as RV144; the recent VOICE trial modification; progress in demonstration projects, public health guidance and regulatory decision-making around PrEP in the United States; and, in addition to its usual features—a map of ongoing prevention trials and a timeline of efficacy trial results worldwide—you’ll find a new table of early-phase studies of ARV-based prevention strategies for HIV-negative people.
July-September 2011, Volume 4, Issue 3
(PDF, HTML)
This edition of Px Wire includes a feature on the new momentum to end the AIDS epidemic in light of the recent HPTN 052 results; an exploration of the progress in AIDS vaccine research and the need for evolving trial designs to accommodate new trial results such as those from HPTN 052 and iPrEx; and, as always, a centerspread with an updated timeline of biomedical HIV prevention efficacy trials and a world map showing where various strategies are being tested.
April-June 2011, Volume 4, Issue 2
(PDF, HTML)
Highlights in this issue include a feature on new momentum to end the AIDS epidemic in light of the new HPTN 052 results showing that early ARV treatment is highly protective against transmitting HIV to one’s sexual partner. You will also find an abbreviated roadmap highlighting sessions on the latest biomedical prevention updates at the upcoming 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. As appears each quarter, this issue includes a center foldout poster with an updated comprehensive timeline of efficacy trials of new biomedical HIV prevention worldwide and a world map showing where various strategies are being tested.
January-March 2011, Volume 4, Issue 1
(PDF, HTML)
This issue of Px Wire takes inventory of the regulatory, trial-planning and scientific agenda-setting steps that are being taken with respect to recent positive trial results. It reviews ongoing and proposed next steps that have been triggered by the Thai prime-boost AIDS vaccine trial, the CAPRISA 004 microbicide trial and the iPrEx trial of once-daily TDF/FTC for pre-exposure prophylaxis. Every issue of Px Wire includes a center poster with an updated comprehensive map and timeline of efficacy trials of biomedical HIV prevention worldwide and a calendar of upcoming events.
2010
October-December 2010, Volume 3, Number 4
Highlights in this issue include an update of the ongoing discussions around the follow-up of the CAPRISA 004 trial finding that 1% tenofovir gel reduces a women's risk of acquiring HIV by 39 percent overall and asks follow-up questions. What additional trials are being considered and why? Who will map the next steps? This issue also touches on the increasing discussions of "treatment as prevention" in reference to the possible use of antiretroviral treatment to reduce the risk of HIV transmission.
July-September 2010, Volume 3, Number 3
In this issue you'll find a brief review of highlights from the biannual International Microbicides Conference (M2010) held in May, including discussions of the potential opportunities and challenges of ARV-based prevention in topical and oral forms, new developments in delivery systems for microbicides and increasing recognition of rectal microbicides as a key area for exploration. This issue also covers what to expect with the forthcoming results of CAPRISA 004.
April-June 2010, Volume 3, Number 2
Highlights in this issue include: next steps in AIDS vaccine trials in the post-Thai vaccine trial (RV144) era; “test and treat” approach for prevention presented at CROI; a preview of AVAC Report 2010; information on the Microbicides 2010 Pre-Conference Advocacy Workshop; new funding for advocacy related to MSM and prevention research; six new clinical trials looking at enhanced prevention strategies.
January-March 2010, Volume 3, Number 1
Highlights in this issue of Px Wire include updates on: the results from MDP 301, a trial of the microbicide PRO 2000, which lay to rest its prospect as a viable microbicide; CDC’s newly modified PrEP trial (TDF2 in Botswana), which changed its status as an efficacy trial to a safety and behavioral study; the evolving effort to understand the Thai prime-boost AIDS vaccine results; recent NIH grants that nearly double global spending on rectal microbicides; and a timeline of 2010 trial milestones—what trial results are expected and what new studies are scheduled to commence?
2009
July-September 2009, Volume 2, Number 3
In addition to its usual features - a map of ongoing prevention trials and a timeline of efficacy trial results worldwide - this issue is designed to provide background and perspectives on some of the key issues and questions that have emerged as work around understanding and interpreting the results of the Thai trial moves forward.
April-June 2009, Volume 2, Number 2
This issue features multiple trial updates, including a review of the key findings from a trial of HSV-2 suppression. There's also a discussion of the results of the HPTN 035 microbicide trial (which tested PRO 2000 and BufferGel) and preparations for the upcoming results of MDP 301, also testing PRO 2000 gel. Additionally, this issue provides information on new trials including HVTN 505 (described in this year's first issue of Px Wire), which began screening participants in June, a new trial on intermittent PrEP scheduled to begin in July, and research to test a nipple shield to help prevent HIV transmission during breastfeeding.
January-March 2009, Volume 2, Number 1
Highlights in this issue of Px Wire include a report on data from the Step vaccine trial and animal studies of relevance to the proposed HVTN 505 trial of the NIH Vaccine Research Center DNA-Ad5 combination strategy presented at the Keystone Symposium on HIV prevention--an annual meeting focused on basic and preclinical science. This issue also reviews newly launched trials, lays out this year's upcoming trial milestones, and gives information on ordering the 2009 AVAC report on the prevention research field, to be released in May.
2008
October-December 2008, Volume 1, Number 4
In this year-end issue, you'll find AVAC's take on the year in prevention research, an update on the proposed AIDS vaccine trial HVTN 505, news on the female condom and microbicide trials and, as always, a freshly updated global map of ongoing efficacy and effectiveness trials, and a comprehensive timeline of biomedical HIV prevention efficacy trials.
July-September 2008, Volume 1, Number 3
Highlights in this issue of Px Wire include a discussion of the no-go decision on the proposed PAVE 100 vaccine trial (though the candidate may yet be tested), updates on women's input into male circumcision for HIV prevention, and AVAC's take on indelible moments and themes from the International AIDS Conference in Mexico City in August.
April-June 2008, Volume 1, Number. 2 / Abril--junio 2008, Vol. 1. No. 2 (en español)
Highlights in this issue of Px Wire include an update on the ongoing discussion regarding the proposed PAVE 100 vaccine trial, details on the first microbicide trial in pregnant women, a Mexico City preview, and notes on two recently released resources for the field, AVAC Report 2008: The Search Must Continue and the Global Campaign for Microbicides' Microbicides Essentials online learning tool.
January-March 2008, Volume 1, Number 1
This is the first issue of our new quarterly, Px Wire, which tracks key developments in the field of HIV prevention research, including the launch of new trials, results of ongoing studies, and an up-to-date tally of trials going on worldwide. Px Wire is designed to complement AVAC's other publications and to help advocates stay on top of the ever-changing field of HIV prevention research. It is the first one-stop source for information on the full range of HIV prevention research going on worldwide, including vaccines, microbicides, pre-exposure prophylaxis (PrEP), herpes simplex virus-2 treatment, male circumcision, cervical barrier methods, and partner treatment.